Exploring the Underreporting of Lambert-eaton Myasthenic Syndrome in Small Cell Lung Cancer (P9-6.002)

Laura Hidalgo; Chelsea Chang; Nicholas Streicher

doi:10.1212/wnl.0000000000212877

June 9, 2026Neurology

Exploring the Underreporting of Lambert-eaton Myasthenic Syndrome in Small Cell Lung Cancer (P9-6.002)

View at Publisher

Ask AI

Bookmark

Share

Key Points

Evaluate the prevalence of Lambert-Eaton Myasthenic Syndrome in small cell lung cancer patients to understand its underrecognition.
Cohort evaluation of small cell lung cancer patients.
Assessment of Lambert-Eaton Myasthenic Syndrome frequency.
Underreporting of Lambert-Eaton Myasthenic Syndrome observed in the cohort.
Prevalence rates indicate significant recognition issues.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Study evaluates Lambert-Eaton Myasthenic Syndrome prevalence in small cell lung cancer patients, indicating possible underrecognition.

Abstract

This study evaluates Lambert-Eaton Myasthenic Syndrome (LEMS) prevalence in a cohort of small cell lung cancer (SCLC) patients to assess underrecognition.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hidalgo et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f0563de https://doi.org/10.1212/wnl.0000000000212877

View at Publisher

Ask AI

Bookmark

Share

Exploring the Underreporting of Lambert-eaton Myasthenic Syndrome in Small Cell Lung Cancer (P9-6.002)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Exploring the Underreporting of Lambert-eaton Myasthenic Syndrome in Small Cell Lung Cancer (P9-6.002)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading